Summary | |
---|---|
Symbol | TP53TG3D |
Name | TP53 target 3D |
Aliases | |
Chromosomal Location | 16p11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm Nucleus |
Domain | - |
Function |
May play a significant role in p53/TP53-mediating signaling pathway. |
Biological Process | - |
Molecular Function | - |
Cellular Component | - |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | TP53TG3D |
Name | TP53 target 3D |
Aliases | |
Chromosomal Location | 16p11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between TP53TG3D and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | TP53TG3D |
Name | TP53 target 3D |
Aliases | |
Chromosomal Location | 16p11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of TP53TG3D in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | TP53TG3D |
Name | TP53 target 3D |
Aliases | |
Chromosomal Location | 16p11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of TP53TG3D in various data sets.
|
Points in the above scatter plot represent the mutation difference of TP53TG3D in various data sets.
|
Summary | |
---|---|
Symbol | TP53TG3D |
Name | TP53 target 3D |
Aliases | |
Chromosomal Location | 16p11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TP53TG3D. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | TP53TG3D |
Name | TP53 target 3D |
Aliases | |
Chromosomal Location | 16p11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TP53TG3D. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TP53TG3D. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | TP53TG3D |
Name | TP53 target 3D |
Aliases | |
Chromosomal Location | 16p11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TP53TG3D. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | TP53TG3D |
Name | TP53 target 3D |
Aliases | |
Chromosomal Location | 16p11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of TP53TG3D expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | TP53TG3D |
Name | TP53 target 3D |
Aliases | |
Chromosomal Location | 16p11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between TP53TG3D and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |